Curanex Pharmaceuticals (NASDAQ:CURX) Posts Earnings Results

Curanex Pharmaceuticals (NASDAQ:CURX) posted its quarterly earnings results on Friday. The company reported ($0.12) earnings per share (EPS) for the quarter, FiscalAI reports.

Curanex Pharmaceuticals Stock Down 0.6%

Shares of NASDAQ CURX traded down $0.00 during mid-day trading on Friday, reaching $0.22. 161,329 shares of the company were exchanged, compared to its average volume of 1,800,257. Curanex Pharmaceuticals has a 1 year low of $0.18 and a 1 year high of $9.18. The firm has a 50-day moving average of $0.24 and a 200 day moving average of $0.33. The stock has a market cap of $6.18 million and a price-to-earnings ratio of -0.81.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Curanex Pharmaceuticals currently has a consensus rating of “Sell”.

Institutional Trading of Curanex Pharmaceuticals

A hedge fund recently bought a new position in Curanex Pharmaceuticals stock. Citadel Advisors LLC acquired a new position in Curanex Pharmaceuticals Inc (NASDAQ:CURX) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 64,067 shares of the company’s stock, valued at approximately $46,000.

Curanex Pharmaceuticals Company Profile

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.